Hematinics

KV Pharmaceutical Co. acquires Niferex product line and two product lines from ALTANA

Published in Drug Week, May 2nd, 2003

KV Pharmaceutical Co. (KVa/KVb) announced that it has concluded an agreement with Schwarz Pharma to acquire the Niferex product line for its Ther-Rx Corp. branded marketing division.

The Niferex product line includes Niferex Tablets, Niferex 150 Capsules, and Niferex 150 Forte. The transaction, valued at approximately $14.3 million and including applicable intellectual property for each of the products, will position KV to build a leading position in this oral hematinic market.

The acquisition adds approximately $5 million in annual net sales and will expand Ther-Rx's current therapeutic areas of women's health and cardiovascular products into the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2003-05-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry